Open AccessRecombinant ING4 suppresses the migration of SW579 thyroid cancer cells via epithelial to mesenchymal transition
Author(s) -
Chuanjiang Wang,
Dong Yang,
Yingwei Luo
Publication year - 2015
Publication title -
experimental and therapeutic medicine
Language(s) - English
Resource type - Journals
eISSN - 1792-1015
pISSN - 1792-0981
DOI - 10.3892/etm.2015.2515
Subject(s) - wnt signaling pathway , cancer research , thyroid cancer , apoptosis , cancer , cell growth , biology , recombinant dna , propidium iodide , cell cycle , epithelial–mesenchymal transition , cancer cell , thyroid , medicine , endocrinology , chemistry , microbiology and biotechnology , signal transduction , metastasis , biochemistry , programmed cell death , genetics , gene
Thyroid cancer is a common endocrine malignancy that has rapidly increased in global incidence. Inhibitor of growth 4 (ING4) has been identified in various types of carcinoma; however, to the best of our knowledge, no previous studies have investigated the effects of ING4 on thyroid cancer. In the present study, SW579 thyroid cancer cells were treated with recombinant ING4 protein, and the results confirmed that recombinant ING4 protein was able to reduce the rate of proliferation, increase the rate of apoptosis and inhibit the mobility of SW579 cells. These results were obtained using a colony formation, fluoroscein isothiocyanate/propidium iodide double staining and Transwell assays, respectively. Furthermore, in the western blot analysis assays, ING4 was demonstrated to inhibit the Wnt/β catenin signaling pathway and epithelial to mesenchymal transition (EMT). Therefore, the present study demonstrated the antitumor activities of recombinant ING4 and identified ING4 could inhibit EMT in thyroid cancer cell. However, additional studies are required to confirm these results in other cell types.